Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In regard to Brown et al
Int J Radiat Oncol Biol Phys
.
2014 Jul 1;89(3):692-3.
doi: 10.1016/j.ijrobp.2014.03.027.
Authors
Shyam S Rao
1
,
Jung Hun Oh
2
,
Andrew Jackson
2
,
Joseph O Deasy
2
Affiliations
1
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
2
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York.
PMID:
24929171
PMCID:
PMC4822491
DOI:
10.1016/j.ijrobp.2014.03.027
No abstract available
Publication types
Letter
Comment
MeSH terms
Carcinoma, Non-Small-Cell Lung / surgery*
Humans
Lung Neoplasms / surgery*
Radiosurgery / methods*
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States